1. 000 ng/ ml, hvilket ca. svarer til en stigning på 2 til 7 millisekunder i 25 plasmakoncentrationsområdet for ranolazin 500 til 1. 000 mg administreret to gange dagligt.
25 when treating patients with a history of congenital or a family history of long QT syndrome, in patients with known acquired QT interval prolongation, and in patients treated with drugs affecting the QTc interval (see section 4.5 also).